Welcome to our dedicated page for Twist Bioscience Corporation news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience Corporation stock.
Twist Bioscience Corporation, symbol TWST, stands at the forefront of synthetic biology with an innovative approach to DNA synthesis. The company's core expertise lies in developing a proprietary semiconductor-based synthetic DNA manufacturing process. This process utilizes a unique 10,000-well silicon platform, markedly different from the traditional 96-well plastic plates. This advanced platform enables the production of synthetic biology tools, such as oligonucleotides, genes, pathways, chassis, and genomes, in a more efficient, cost-effective, and high-throughput manner.
The implications of Twist Bioscience's technology are profound, offering the potential to revolutionize various fields. By synthesizing DNA on silicon, the company overcomes existing production inefficiencies, ensuring rapid and high-quality DNA synthesis. This capability is crucial for accelerating developments in personalized medicine, sustainable chemical production, agricultural improvements, in vivo diagnostics, biodetection, and even data storage.
Based primarily in the United States, Twist Bioscience derives the majority of its revenue from its home market. The company's strategic partnerships and ongoing projects reflect its commitment to pioneering advancements in synthetic biology. Having positioned itself as a leader in the field, Twist Bioscience continues to support researchers and industries by providing high-quality synthetic DNA rapidly, enabling them to seize emerging opportunities.
For more information, please visit Twist Bioscience.
Twist Bioscience (NASDAQ: TWST), a mid-cap life sciences company, has announced that CEO and co-founder Emily M. Leproust, Ph.D. will deliver a presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for January 13, 2025, at 5:15 p.m. Pacific Time in San Francisco, California.
The event will be accessible via webcast through the company's investor relations website's 'Investor Calendar' section. Following the live presentation, a replay will remain available for 30 days.
Twist Bioscience (NASDAQ: TWST) announced its financial results for Q4 and full year fiscal 2024 ended September 30, 2024. The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss the results and provide a business update. Participants can access detailed earnings reports and investor presentations through the company's website. Those joining via telephone must register in advance to receive dial-in information.
Twist Bioscience (NASDAQ: TWST), a synthetic DNA manufacturer, announced its participation in the 7th Annual Evercore HealthCONx Conference. CEO and co-founder Emily M. Leproust, Ph.D., along with CFO Adam Laponis, will engage in a fireside chat on December 3, 2024, at 10:00 a.m. Eastern Time in Coral Gables, Florida. The event will be accessible via live webcast through the company's investor relations website, with a replay available for 30 days after the presentation.
Twist Bioscience (NASDAQ: TWST) has announced new equity awards as employment inducements under Nasdaq Rule 5635(c)(4). The company granted 110,300 restricted stock units (RSUs) to 43 new employees and up to 37,500 performance stock units (PSUs) to VP Colby Souders. The RSUs vest over 48 months, with 25% vesting after one year and 1/16 vesting quarterly thereafter. The PSUs vest based on performance metrics for FY2024-2026, with potential earnings of 80%-150% of target, subject to continued employment.
Twist Bioscience (NASDAQ: TWST) has launched the FlexPrep™ Ultra-High Throughput Library Preparation Kit, featuring proprietary Normalization by Ligation™ technology. The kit enables processing of thousands of samples at low cost, eliminating the need for upfront sample quantitation and allowing early sample pooling. Researchers can run up to 1,152 samples in a single 96-well plate, reducing consumables by 12x and pipette tips usage from 17,000 to under 4,000. The company is collaborating with Gencove to provide genomic analysis software, offering an end-to-end workflow solution for agricultural and population genomics applications.
Twist Bioscience (NASDAQ: TWST) has announced it will release its fiscal 2024 fourth quarter and full year financial results on November 18, 2024, before market opening. The company will host a conference call and live audio webcast for analysts and investors at 8:00 AM Eastern Time. Participants interested in joining via telephone must register through the company's Investor Relations website. A webcast replay will be available for two weeks following the call.
Twist Bioscience (NASDAQ: TWST) has entered into a royalty purchase agreement with XOMA Royalty (NASDAQ: XOMA). Under the agreement, XOMA Royalty will provide Twist with an upfront payment of $15 million in exchange for the right to receive half of the future potential milestone and royalty payments from Twist's existing antibody discovery and biopharma services collaborations.
Twist will retain all upfront, service, and other revenue from these collaborations, as well as full rights to future biopharma collaborations with milestone and royalty terms. The agreement does not apply to synbio, NGS, or data storage revenue. This deal aims to provide Twist with immediate capital to support continued innovation and profitable growth across the company.
Twist Bioscience (NASDAQ: TWST) has appointed Mike Fero, Ph.D., as Chief Information Officer. Dr. Fero brings over 30 years of experience in startups, commercial software development, biology and physics research, and deep-tech businesses. His background includes building scalable enterprise software platforms and understanding systems biology and artificial intelligence. Dr. Fero was previously a Twist customer, giving him unique insights into the company's mission.
Before joining Twist, Dr. Fero co-founded and served as CEO of TeselaGen Biotechnology for a decade, developing an enterprise software platform for DNA design and management. He has also held positions at Stanford University, Neomorphic, HyperParallel, and MIT. Dr. Fero holds a Ph.D. in Physics and a B.A. in Math and Physics from UC Irvine.
Twist Bioscience (NASDAQ: TWST) has achieved LEED certification for its Wilsonville, OR facility, demonstrating its commitment to sustainability in operations and maintenance. The certification, awarded by the U.S. Green Building Council, recognizes the facility's adherence to LEED v4.1 Operations + Maintenance standards.
CEO Emily M. Leproust emphasized that this achievement aligns with Twist's mission to improve health and sustainability. The company previously quantified the carbon footprint of gene production using their platform, showing significant environmental benefits compared to traditional methods. This LEED certification further solidifies Twist's commitment to providing customers with DNA produced in a sustainable facility using fewer chemical reagents.
Twist Bioscience (NASDAQ: TWST) has released its 2024 corporate responsibility report, highlighting its commitment to sustainability, social responsibility, and ethics. The company's silicon-based DNA manufacturing platform offers a more sustainable alternative to legacy methods, using 99.8% less reagents than 96-well plate approaches.
Key points:
- Twist's oligo manufacturing process for NGS target enrichment panels emits significantly less CO2 compared to industry standards
- The company disclosed its Scope 1 and Scope 2 emissions for the first time
- Twist prioritizes biosecurity, cybersecurity, and data protection
- The company fosters a diverse workforce, with 56% of U.S. employees identifying as individuals of color
- Twist invested over $220,000 in employee learning and development in fiscal 2023
FAQ
What is the current stock price of Twist Bioscience Corporation (TWST)?
What is the market cap of Twist Bioscience Corporation (TWST)?
What does Twist Bioscience Corporation do?
How does Twist Bioscience's technology differ from traditional methods?
What are some applications of Twist Bioscience's synthetic DNA?
Where does Twist Bioscience generate most of its revenue?
How does Twist Bioscience contribute to personalized medicine?
What is the significance of using silicon in DNA synthesis?
Can Twist Bioscience's technology be used in agriculture?
What ongoing projects does Twist Bioscience have?
How does Twist Bioscience's platform support researchers?
Where can I find more information about Twist Bioscience?
